Presentations to Demonstrate How Next-Generation Bayesian and Causal AI Increase Flexibility and Speed in Clinical Development
PhaseV, a leader in AI/ML for clinical development, today announced it will participate in several upcoming biopharma conferences shaping the conversation on the future of clinical trial development and execution. PhaseV executives will present advanced research and lead key industry discussions, showcasing how their expertise in next-generation Bayesian and causal AI increases the flexibility, robustness, and speed of clinical trials.
https://mma.prnewswire.com/media/2267452/PhaseV_logo.jpg
“Clinical trials are inherently complex and uncertain. By combining Bayesian statistical frameworks with advanced AI-driven simulation, we help sponsors to reduce risk and accelerate their path to market,” said Raviv Pryluk, PhD, CEO and Co-founder of PhaseV. “We are excited to share how our work is helping to drive faster and more successful clinical development and execution, unlocking new opportunities for the biopharma community and helping to bring promising new therapies to patients.”
Event participation includes:
Pharma Tech Forum: From Molecule to Model – Advancing Biotech with Computation
— Date: September 17, 2025
— Location: Tel Aviv, Israel
— Panel: Discussion with Tech Leaders in Biotech: From Vision to Implementation
— Moderator: Sharon Kredo-Russo, VP of Ideation & Scouting at AION Labs
— Panelists: Elad Berkman, PhD, CTO and Co-founder of PhaseV will join a panel of biotech leaders.
ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop (RISW 2025)
— Date: September 24-26
— Location: Rockville, MD, USA
— Presentation:PhaseV executives will present on Computing, Optimization, and Causal Inference for Adaptive Clinical Trials
Fierce Biotech Week
— Date: October 7-9, 2025
— Location: Boston, MA, USA
— Panel: Raviv Pryluk, PhD, CEO will moderate a panel on InnovationinClinicalDesignandManagement, a broader discussion on the future of clinical development.
Bayesian Biostatistics Conference Bayes
— Date: October 22-24, 2025
— Location: Leiden, The Netherlands
— Presentation: PhaseV executives will present onOptimal Bayesian Adaptive Sequential Trial Design using Stepwise Monte Carlo for Increased Flexibility and Robustness
About PhaseVPhaseV is developing advanced AI/ML solutions to optimize clinical development. Biopharma sponsors and CROs are leveraging PhaseV's platform to rapidly design and execute adaptive, Bayesian and fixed clinical trials, analyze data to uncover heterogeneous treatment effects, stratify patients, and inform future R&D and portfolio decisions. PhaseV's platform has reduced trial costs by 50%, decreased enrollment size and trial duration by 40%, and increased the probability of trial success by over 30%. To date, the company has delivered results for more than 40 leading pharma/biotech sponsors and CROs spanning multiple therapeutic areas, including neurology, oncology, immunology, GI, rare diseases, and others.
Learn more athttps://www.phasevtrials.comand follow us onLinkedIn.
Media Contact:Ellie HansonFINN Partners for PhaseVellie.hanson@finnpartners.com
Logo: https://mma.prnewswire.com/media/2267452/PhaseV_logo.jpg
https://edge.prnewswire.com/c/img/favicon.png?sn=LN73008&sd=2025-09-15
View original content to download multimedia:https://www.prnewswire.com/news-releases/phasev-to-present-on-advanced-aiml-for-clinical-development-at-upcoming-biopharma-events-302556210.html
SOURCE PhaseV
https://rt.newswire.ca/rt.gif?NewsItemId=LN73008&Transmission_Id=202509150830PR_NEWS_USPR_____LN73008&DateId=20250915